{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:fda.keytruda:10 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Afda.keytruda%3A10",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003855,
    "timestamp_received": "2026-04-24T00:48:09.808009+00:00Z",
    "timestamp_returned": "2026-04-24T00:48:09.811864+00:00Z",
    "trace_id": "1862b519-7729-480b-a4a9-5a824ba6a0ce"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:fda.keytruda:10",
      "indication": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",
      "initial_approval_date": null,
      "initial_approval_url": null,
      "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.",
      "raw_biomarkers": "PD-L1 (CPS >= 1)",
      "raw_cancer_type": "recurrent or metastatic cervical cancer",
      "raw_therapeutics": "Keytruda (pembrolizumab)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:fda.keytruda",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Keytruda (pembrolizumab) [package insert]. FDA.",
        "title": null,
        "aliases": [],
        "description": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514Orig1s186lbl.pdf. Revised February 2026. Accessed March 2, 2026.",
        "urls": [
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514Orig1s186lbl.pdf",
          "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "fda",
              "type": "Agent",
              "agentType": "organization",
              "name": "Food and Drug Administration",
              "description": "Regulatory agency that approves drugs for use in the United States.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2026-04-09",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Merck Sharp & Dohme Corp.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Keytruda",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "pembrolizumab",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2014-09-04",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": 125514,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2026-02-10",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}